Ozon Pharmaceuticals

Ozon Pharmaceuticals is a leading Russian pharmaceutical manufacturer specializing in the production of high-quality generic medications across a wide array of therapeutic areas. Founded in 2001 and headquartered in the Samara region, the company operates several large-scale manufacturing facilities, including Ozon Pharm and Ozon Medika, which adhere to international GMP standards. Its extensive portfolio comprises over 500 products, with a strong focus on cardiovascular, neurological, and gastrointestinal health. In October 2024, the company successfully launched an initial public offering on the Moscow Exchange, highlighting its position as a key player in the Russian drug market. Ozon Pharmaceuticals is also expanding into high-tech sectors, including the development of biosimilars and oncology treatments through its Mabscale initiative.